[go: up one dir, main page]

CL2019003789A1 - Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. - Google Patents

Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.

Info

Publication number
CL2019003789A1
CL2019003789A1 CL2019003789A CL2019003789A CL2019003789A1 CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1 CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A CL2019003789 A CL 2019003789A CL 2019003789 A1 CL2019003789 A1 CL 2019003789A1
Authority
CL
Chile
Prior art keywords
pai
overexpression
conditions associated
plasminogen
treatment
Prior art date
Application number
CL2019003789A
Other languages
English (en)
Inventor
Lyne Gagnon
Brigitte Grouix
Pierre Laurin
Original Assignee
Prometic Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biotherapeutics Inc filed Critical Prometic Biotherapeutics Inc
Publication of CL2019003789A1 publication Critical patent/CL2019003789A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCIÓN SE REFIERE AL USO DEL PLASMINÓGENO, UNA VARIANTE DE ESTE, O UN ANÁLOGO QUE TIENE UNA ACTIVIDAD DE PLASMINÓGENO PARA LA PREVENCIÓN O TRATAMIENTO DE UNA AFECCIÓN O UNA ENFERMEDAD QUE SE CARACTERIZA CON UN MAYOR NIVEL DE PAI-1. LAS AFECCIONES Y ENFERMEDADES QUE SE CARACTERIZAN CON UN MAYOR NIVEL DE PAI-1 SE REAGRUPAN DENTRO DE DOS CATEGORÍAS: LAS ENFERMEDADES ASOCIADAS A UNA CAPACIDAD ALTERADA DE REMODELACIÓN TISULAR Y VASCULAR, Y LOS TRASTORNOS METABÓLICOS Y HORMONALES ASOCIADOS A UN MAYOR NIVEL DE PAI-1.
CL2019003789A 2017-06-23 2019-12-20 Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1. CL2019003789A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762523901P 2017-06-23 2017-06-23

Publications (1)

Publication Number Publication Date
CL2019003789A1 true CL2019003789A1 (es) 2020-07-10

Family

ID=64737041

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003789A CL2019003789A1 (es) 2017-06-23 2019-12-20 Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.

Country Status (20)

Country Link
US (1) US11826404B2 (es)
EP (1) EP3641888B1 (es)
JP (1) JP2020524689A (es)
KR (1) KR20200019217A (es)
CN (1) CN110831668B (es)
AU (1) AU2018287316B2 (es)
BR (1) BR112019027229A2 (es)
CA (1) CA3068153A1 (es)
CL (1) CL2019003789A1 (es)
DK (1) DK3641888T3 (es)
ES (1) ES2965937T3 (es)
FI (1) FI3641888T3 (es)
IL (1) IL271470B2 (es)
MX (1) MX2019015741A (es)
MY (1) MY203136A (es)
RU (1) RU2020100080A (es)
SG (1) SG11201912813SA (es)
TW (1) TWI868051B (es)
WO (1) WO2018234861A1 (es)
ZA (1) ZA202000280B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11389515B2 (en) 2016-12-15 2022-07-19 Talengen International Limited Method for mitigating heart disease
TW201822812A (zh) 2016-12-15 2018-07-01 深圳瑞健生命科學硏究院有限公司 一種預防和治療肥胖症的方法
CA3047181A1 (en) 2016-12-15 2018-06-21 Talengen International Limited Method and drug for preventing and treating obesity
KR20220137950A (ko) * 2020-02-06 2022-10-12 탈렌젠 인터내셔널 리미티드 다발성 경화증의 예방 및 치료 방법 및 약물
JP2023518564A (ja) * 2020-03-24 2023-05-02 タレンゲン インターナショナル リミテッド ミスフォールドタンパク質およびその凝集体の分解を促進する方法及び薬剤
WO2021190561A1 (zh) * 2020-03-24 2021-09-30 泰伦基国际有限公司 一种治疗帕金森病的方法和药物
TWI868333B (zh) * 2020-03-24 2025-01-01 大陸商深圳瑞健生命科學研究院有限公司 一種治療阿茲海默症的方法和藥物
CN112174979B (zh) * 2020-10-27 2021-09-07 黑龙江中医药大学 一种治疗多囊卵巢综合征的药物及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5520912A (en) 1993-07-02 1996-05-28 Immuno Aktiengesellschaft Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
WO2001036351A2 (en) 1999-11-19 2001-05-25 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
WO2001058476A2 (en) * 2000-02-11 2001-08-16 The European Molecular Biology Laboratory Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
GB0509438D0 (en) * 2005-05-09 2005-06-15 Prometic Biosciences Ltd Affinity adsorbets for fibrinogen
ES2451015T3 (es) * 2006-08-28 2014-03-26 Omnio Healer Ab Candidatos contra la infección
AU2007290882B2 (en) 2006-08-28 2013-02-21 Omnio Healer Ab Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
KR20160035077A (ko) * 2013-08-13 2016-03-30 사노피 플라스미노겐 활성인자 저해제-1(pai-1)에 대한 항체 및 그의 용도
TWI801331B (zh) * 2015-11-03 2023-05-11 美商波麥堤克生物治療股份有限公司 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
TW201722464A (zh) * 2015-11-10 2017-07-01 波麥堤克生化科學有限公司 用於傷口癒合之纖維蛋白溶酶原給藥方案
WO2018107695A1 (zh) 2016-12-15 2018-06-21 深圳瑞健生命科学研究院有限公司 一种预防和治疗肾纤维化的方法
EP3556395A4 (en) * 2016-12-15 2020-07-22 Talengen International Limited METHOD OF PREVENTION AND TREATMENT OF PULMONARY FIBROSIS
CA3047181A1 (en) * 2016-12-15 2018-06-21 Talengen International Limited Method and drug for preventing and treating obesity

Also Published As

Publication number Publication date
CA3068153A1 (en) 2018-12-27
EP3641888B1 (en) 2023-10-11
RU2020100080A (ru) 2021-07-23
SG11201912813SA (en) 2020-01-30
EP3641888A1 (en) 2020-04-29
IL271470B1 (en) 2025-03-01
CN110831668A (zh) 2020-02-21
MX2019015741A (es) 2020-11-11
AU2018287316A1 (en) 2020-02-06
TW201904990A (zh) 2019-02-01
AU2018287316B2 (en) 2024-09-19
WO2018234861A1 (en) 2018-12-27
TWI868051B (zh) 2025-01-01
DK3641888T3 (da) 2024-01-02
ZA202000280B (en) 2021-08-25
IL271470B2 (en) 2025-07-01
RU2020100080A3 (es) 2021-11-02
MY203136A (en) 2024-06-10
ES2965937T3 (es) 2024-04-17
CN110831668B (zh) 2024-04-12
JP2020524689A (ja) 2020-08-20
KR20200019217A (ko) 2020-02-21
US11826404B2 (en) 2023-11-28
IL271470A (en) 2020-01-30
FI3641888T3 (fi) 2023-12-19
BR112019027229A2 (pt) 2020-07-07
EP3641888A4 (en) 2021-03-10
US20210330761A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CL2019003789A1 (es) Tratamiento con plasminógeno de afecciones asociadas a la sobreexpresión de pai-1.
IL280710A (en) Methods and compositions for treating mitochondrial disease or disorders and heteroplasmy
MX2022007989A (es) Composiciones y metodos para tratar pterigion.
PL3673080T3 (pl) Oligomery antysensowne do leczenia stanów i chorób
CY1120950T1 (el) Θεραπεια ινωσης
IL268850A (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
BR112018005114A2 (pt) um novo polipeptídeo de endolisina
IL283929A (en) Treatment of 22q11.2 deletion syndrome with cannabidiol
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2017014645A (es) Profarmacos de alvocidib que tienen una biodisponibilidad aumentada.
EA201692436A1 (ru) Медицинское применение
MX2021006408A (es) Terapia de combinacion de radioinmunoconjugados con inhibidores de da?os y reparaciones del adn.
MX2022004143A (es) Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso.
CR20190471A (es) Moduladores de la expresión de pcsk9
JOP20210050A1 (ar) معدلات تعبير pnpla3
IL272601A (en) Pharmaceutical compositions for the treatment of ophthalmic conditions
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
MX387839B (es) Laminina para usarse en el tratamiento de una enfermedad, un trastorno o una afección de un endotelio de córnea.
IL286268A (en) Pridopidine for use in the treatment of mitochondrial associated diseases and disorders, including symptoms thereof
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
IL287704A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
EA201790893A1 (ru) Способы лечения офтальмологических расстройств
EP3592377A4 (en) TISSUE KALLICREIN DOSAGE FORMS 1